FDA approves labeling changes for ED drugs

Share this article:
The FDA has approved some labeling changes to erectile dysfunction drugs— including Viagra, Cialis, and Levitra—to display more prominently an existing risk on the potential for sudden hearing loss. The changes were also made to Pfizer's Revatio, which contains the same active ingredient (sildenafil) as Viagra.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions